Provided by Tiger Fintech (Singapore) Pte. Ltd.

INNOVENT BIO

50.250
+0.4000.80%
Volume:24.88M
Turnover:1.23B
Market Cap:82.31B
PE:-811.03
High:51.000
Open:49.200
Low:47.750
Close:49.850
Loading ...

Stock Track | Innovent Biologics Soars 18.95% Following Strong 2024 Financial Results

Stock Track
·
27 Mar

Stock Track | Innovent Biologics Soars Nearly 19% on Impressive 2024 Financial Results

Stock Track
·
27 Mar

Innovent Bio's 2024 Loss Narrows as Revenue Surges 52%; Shares Jump 14%

MT Newswires Live
·
27 Mar

BRIEF-Innovent Announces 2024 Annual Results And Business Updates

Reuters
·
26 Mar

Innovent Announces 2024 Annual Results and Business Updates

THOMSON REUTERS
·
26 Mar

Press Release: Innovent Announces 2024 Annual Results and Business Updates

Dow Jones
·
26 Mar

Innovent Biologics FY Adjusted Net Income RMB 331.6 Million

THOMSON REUTERS
·
26 Mar

Hutchmed, Innovent Combo Therapy Hits PFS Target in Renal Cancer Study

MT Newswires Live
·
19 Mar

Hutchmed (China) Says Frusica-2 Phase II/III Study Met Primary Endpoint

Reuters
·
19 Mar

Innovent and HUTCHMED Jointly Announce That the Frusica-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China

THOMSON REUTERS
·
19 Mar

Innovent Biologics' NDA for Thyroid Eye Disease Drug Gets China Nod

MT Newswires Live
·
14 Mar

Innovent Biologics - Igf-1R Monoclonal Antibody Sycume Received Approval by Nmpa for Thyroid Eye Disease

THOMSON REUTERS
·
14 Mar

BRIEF-Innovent Is Said To Consider Licensing Partnership For Cancer Drug- Bloomberg News

Reuters
·
11 Mar

Innovent Is Said to Consider Licensing Partnership for Cancer Drug- Bloomberg News

THOMSON REUTERS
·
11 Mar

Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of Ibi363 (Pd-1/Il-2Α-Bias Bispecific Antibody Fusion Protein) in Melanoma

THOMSON REUTERS
·
03 Mar

Innovent Biologics Anti-Cancer Drug's NDA Accepted by China's NMPA; Shares Slide 3%

MT Newswires Live
·
24 Feb

BRIEF-Innovent Biologics Says NMPA China Accepts New Drug Application For Ipilimumab Injection

Reuters
·
24 Feb

Nmpa Accepts Nda and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic Ctla-4 Inhibitor, in Combination With Sintilimab as Neoadjuvant Treatment for Colon Cancer

THOMSON REUTERS
·
24 Feb

Innovent Biologics - Nmpa China Accepts New Drug Application & Grants Priority Review Designation to Ipilimumab Injection

THOMSON REUTERS
·
24 Feb

Nomura Adjusts Innovent Biologics' Price Target to HK$54.60 From HK$58.09, Keeps at Buy

MT Newswires Live
·
18 Feb